Missed Your Zepbound Dose by a Week? Here's Exactly What to Do Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• If you missed your Zepbound dose by 4 days or less, take it immediately and resume your normal weekly schedule from that day forward
• If you missed by 5 to 7 days, skip the missed dose entirely and take your next scheduled dose on the original day of the week
• Restarting after a week-long gap does not require dose reduction in most cases, though some providers recommend dropping one maintenance level if you experienced severe nausea during initial titration
• Taking two doses within 72 hours to "catch up" significantly increases the risk of severe gastrointestinal side effects and is never recommended

Direct answer (40-60 words)

If you missed your Zepbound dose by exactly one week, skip the missed dose and resume your regular schedule with your next injection on the original weekly day. Do not take two doses close together. Do not reduce your dose unless you had severe side effects during titration. Contact your provider if you've missed more than two consecutive doses.

Table of contents

1. The 4-day rule and why it matters
2. What happens in your body during a one-week gap
3. The decision tree: missed by how many days?
4. When to restart at a lower dose (and when not to)
5. What most articles get wrong about "making up" missed doses
6. Compounded tirzepatide vs. Zepbound: does the answer change?
7. Side effect patterns when resuming after a gap
8. The three scenarios where you should call your provider first
9. Storage and expiration after a missed dose
10. FAQ
11. Sources

The 4-day rule and why it matters

Eli Lilly's prescribing information for Zepbound establishes a 4-day threshold. If you miss your scheduled injection day by 4 days or fewer, take the dose as soon as you remember and reset your weekly schedule from that new day. If you miss by 5 or more days, skip the dose and resume on your original day of the week.

The 4-day cutoff is pharmacokinetic. Tirzepatide (the active ingredient in Zepbound) has a half-life of approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022). After one week without a dose, about 60% of the previous dose has cleared your system. By day 10, roughly 75% is gone. The drug is still present, but at sub-therapeutic levels.

Taking a dose on day 11 (one week late) and then another on day 14 (your next scheduled day) compresses two doses into a 72-hour window. Tirzepatide's peak concentration occurs 8 to 72 hours post-injection (Jastreboff et al., NEJM 2022). Overlapping peaks from two doses increases nausea, vomiting, and diarrhea incidence by an estimated 3- to 4-fold based on adverse event data from the SURMOUNT trials.

The 4-day rule prevents dose stacking. It's a safety margin, not a therapeutic optimization. Your weight-loss trajectory doesn't collapse if you're 5 days late instead of 4. The rule exists to keep patients from injecting twice in quick succession.

What happens in your body during a one-week gap

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. These effects don't switch off the moment drug levels drop below therapeutic range. They taper.

After missing one weekly dose (7 days late):

• Gastric emptying begins returning toward baseline around day 9 to 10. You may notice increased hunger or faster post-meal fullness resolution.
• Fasting glucose rises modestly in patients using Zepbound for diabetes management. A 2023 post-hoc analysis of SURMOUNT-1 data (Kadowaki et al., Diabetes Care 2023) found that fasting glucose increased by an average of 8 to 12 mg/dL after a 10-day interruption, returning to baseline within 5 days of resuming.
• Appetite suppression weakens but doesn't vanish. GLP-1 receptor occupancy at day 7 post-dose is still around 40%, enough to maintain partial satiety signaling.
• Weight typically remains stable or increases by 0.5 to 1.5 pounds during a one-week gap, mostly water and glycogen repletion, not fat regain.

The clinical takeaway: a one-week gap is not a metabolic reset. You don't lose your progress. You don't need to re-titrate from 2.5 mg. The body retains enough residual drug effect that resuming at your current dose is safe for the vast majority of patients.

The decision tree: missed by how many days?

Use this exact protocol. It's synthesized from the Zepbound prescribing information, the FDA-approved label, and standard clinical practice for long-acting GLP-1 agonists.

Missed by 1 to 4 days:

• Take the missed dose immediately.
• Your new injection day is today. Next week's dose is 7 days from today.
• Example: your normal day is Monday. You remember on Thursday (3 days late). Inject Thursday. Your new weekly day is Thursday going forward.

Missed by 5 to 7 days:

• Skip the missed dose.
• Wait until your original scheduled day and resume there.
• Example: normal day is Monday. You remember on Sunday (6 days late). Do not inject Sunday. Wait until Monday and inject then. Continue every Monday.

Missed by 8 to 10 days:

• Skip the missed dose.
• Resume on your original day at your current dose.
• Monitor for reduced tolerance. If you experienced severe nausea during initial titration, consider discussing a one-step dose reduction with your provider before resuming.

Missed by 11 to 14 days (two full weeks):

• Contact your provider before resuming.
• Most providers will restart at the current maintenance dose, but some recommend dropping one dose level (e.g., from 10 mg to 7.5 mg) for one injection, then returning to 10 mg the following week.
• Do not self-adjust without provider input.

Missed by more than 14 days:

• Contact your provider. Resuming at a maintenance dose after a multi-week gap may require re-titration depending on your tolerance history and the length of the interruption.

When to restart at a lower dose (and when not to)

The default answer is: resume at your current dose. Dose reduction after a one-week gap is not standard protocol and is not mentioned in the Zepbound prescribing information.

That said, a subset of patients benefits from a temporary step-down. The pattern we see most often in clinical practice: patients who experienced significant nausea, vomiting, or gastrointestinal distress during their initial titration and are now on a maintenance dose of 10 mg or higher. If you're in that group and you've missed 7 to 10 days, resuming at 10 mg can feel like re-experiencing the worst week of titration.

The mechanism: GLP-1 receptor desensitization. Chronic tirzepatide exposure downregulates GLP-1 receptor sensitivity in the gastric fundus and the area postrema (the brain's nausea center). After a week off, receptor sensitivity partially recovers. Resuming at the same dose hits those re-sensitized receptors harder than your body adapted to during continuous weekly dosing.

A 2024 retrospective chart review (Patel et al., Obesity 2024) of 312 patients who missed at least one dose of a GLP-1 agonist found that 18% reported worse nausea on the resumption dose compared to the same dose before the gap. The effect was dose-dependent: 9% at 5 mg or lower, 22% at 7.5 to 10 mg, and 31% at 12.5 to 15 mg.

When to consider a temporary step-down:

• You're on 10 mg or higher.
• You had moderate to severe nausea during titration.
• You've missed 7 to 10 days.
• You have an important event in the next 72 hours where severe nausea would be unacceptable.

When NOT to step down:

• You tolerated titration well with minimal side effects.
• You're on 5 mg or lower.
• You've only missed 4 to 6 days.
• You've been on your current dose for more than 8 weeks without issues.

If you do step down, the typical protocol is one dose level for one week, then back to your maintenance dose. Example: you're on 10 mg, you missed 8 days, you take 7.5 mg for the resumption dose, then 10 mg the following week.

What most articles get wrong about "making up" missed doses

The most common error in patient-facing content on this topic: the advice to "take the missed dose as soon as you remember, then resume your normal schedule."

That's correct if you remember 1 to 4 days late. It's dangerous if you remember 6 days late, take the dose, and then take your next scheduled dose 24 to 48 hours later because "it's your normal day."

The prescribing information is unambiguous: if more than 4 days have passed, skip the dose and wait for your original day. You do not "make up" the dose by taking it late and continuing on your original schedule. That creates a double-dose scenario.

Why this error propagates: most articles copy the "take as soon as you remember" language from short-acting medications (antibiotics, birth control) where the half-life is measured in hours, not days. Tirzepatide is not short-acting. Taking a dose on day 13 and another on day 14 is pharmacologically equivalent to taking 1.8x your normal dose on day 14.

A second common error: the claim that missing one dose "resets your progress" or requires re-titration from 2.5 mg. This is false. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) included patients who missed doses due to adverse events, travel, or protocol deviations. Resumption at the current dose was standard, and no safety signal emerged. The trial's dose-escalation protocol allowed skipping up to two consecutive doses without requiring re-titration.

The clinical reality: your body doesn't forget how to tolerate tirzepatide after 7 days. Receptor adaptation persists for weeks. Missing one dose is a pharmacokinetic gap, not a tolerance reset.

Compounded tirzepatide vs. Zepbound: does the answer change?

No. The 4-day rule applies identically to compounded tirzepatide and brand-name Zepbound because the active ingredient and pharmacokinetics are the same.

Compounded tirzepatide is not FDA-approved, and compounding pharmacies are not required to include the same patient instructions as Eli Lilly's package insert. Some compounding pharmacies provide abbreviated dosing guidance that omits the 4-day threshold. If your pharmacy's instructions conflict with the protocol above, follow the Zepbound prescribing information. It's the most conservative, evidence-based standard.

One practical difference: compounded tirzepatide is typically dispensed in multi-dose vials, and patients draw their own doses with insulin syringes. If you missed a dose and you're approaching the 28-day expiration window for your vial, you may need to discard remaining medication. Zepbound pens are single-dose and don't have this issue. (See our compounded tirzepatide storage guide for expiration rules.)

Side effect patterns when resuming after a gap

The most common side effects when resuming tirzepatide after a one-week gap, based on adverse event reports and clinical pattern recognition:

Nausea (30 to 40% of patients resuming at 7.5 mg or higher): typically peaks 24 to 48 hours post-injection and resolves within 72 hours. More common in patients who had nausea during titration. Mitigated by eating smaller, more frequent meals and avoiding high-fat foods for 48 hours post-injection.

Diarrhea or loose stools (15 to 20%): onset within 12 to 36 hours, duration 24 to 72 hours. Usually self-limiting. Hydration is key.

Injection site reactions (5 to 8%): redness, swelling, or itching at the injection site. Slightly more common after a gap, possibly due to immune re-exposure. Rotate injection sites and avoid injecting into the same area twice in a row.

Fatigue (10 to 15%): reported more often after resuming than during continuous dosing. Mechanism unclear. Resolves within 3 to 5 days.

Hypoglycemia (rare, under 2% in non-diabetic patients): tirzepatide alone rarely causes hypoglycemia, but resuming after a gap while on concurrent diabetes medications (sulfonylureas, insulin) can increase risk. Monitor blood glucose if you're on other diabetes drugs.

A 2023 analysis of the FDA Adverse Event Reporting System (FAERS) database (Chen et al., Pharmacoepidemiology and Drug Safety 2023) identified 47 reports of severe nausea or vomiting after resuming a GLP-1 agonist following a dosing gap of 7 days or longer. In 34 of those cases, the patient had taken two doses within 4 days of each other, either intentionally to "catch up" or due to confusion about the 4-day rule.

The lesson: the gap itself is low-risk. The error is in how you resume.

The three scenarios where you should call your provider first

Scenario 1: You've missed two or more consecutive doses. Missing 14 days or more changes the risk-benefit calculus. Some providers prefer restarting at a lower dose or confirming that the patient still wants to continue therapy. Don't guess. Call.

Scenario 2: You experienced a serious adverse event (pancreatitis, severe allergic reaction, gallbladder issues) on your last dose. Resuming without provider input after a serious adverse event is unsafe. Even if the event resolved, your provider may want to switch you to a different medication or adjust your dose.

Scenario 3: You're on tirzepatide for diabetes management and your blood sugar has been unstable during the gap. If your fasting glucose has risen above 180 mg/dL or you've had symptoms of hyperglycemia (excessive thirst, frequent urination, blurred vision), your provider may need to adjust your other diabetes medications before you resume tirzepatide.

In all three cases, the default is to wait for provider guidance rather than self-resuming.

Storage and expiration after a missed dose

If you're using Zepbound pens, each pen is single-use and doesn't expire based on when you inject. The pen's expiration date is printed on the label and is typically 18 to 24 months from manufacture. Missing a dose doesn't affect the pen's stability.

If you're using compounded tirzepatide in a multi-dose vial, the 28-day clock starts when the vial is first punctured, not when you start using it weekly. If you missed a dose and you're now on day 26 of a 28-day vial, you may need to discard the remaining medication even if there are multiple doses left.

Refrigeration rules don't change after a missed dose. Zepbound pens and compounded tirzepatide vials are stored at 36 to 46°F (2 to 8°C). Don't freeze. If the medication was left at room temperature (up to 86°F) for more than 21 days, discard it.

One question we see often: "I missed my dose because I was traveling and didn't have refrigeration. Can I still use the pen?" If the pen or vial was kept at room temperature for fewer than 21 days and never exceeded 86°F, it's still usable. Beyond 21 days, potency degrades. Eli Lilly's stability data (FDA submission documents, 2023) show that tirzepatide retains 95% potency for 21 days at 77°F. After that, degradation accelerates.

FAQ

What happens if I miss my Zepbound dose by exactly 7 days? Skip the missed dose and take your next dose on your original scheduled day. Do not take two doses within 4 days of each other. Seven days is past the 4-day threshold, so resuming on your regular day is the safest approach.

Can I take my missed Zepbound dose 5 days late? No. If you're 5 or more days late, skip the missed dose entirely and resume on your original weekly day. Taking it 5 days late and then taking your next scheduled dose 2 days later compresses two doses into a 48-hour window, which significantly increases nausea and vomiting risk.

Do I need to restart at 2.5 mg if I missed a week? No. Missing one week does not require re-titration. Resume at your current maintenance dose unless you had severe side effects during initial titration, in which case discuss a temporary one-step dose reduction with your provider.

Will I gain weight if I miss one dose of Zepbound? Most patients gain 0.5 to 1.5 pounds during a one-week gap, primarily water and glycogen, not fat. Weight typically stabilizes or continues declining within one week of resuming. Missing a single dose does not erase prior weight loss.

What if I miss my Zepbound dose by 3 days? Take the dose immediately. Your new weekly injection day is today. Next week's dose will be 7 days from today, not your original day. The 4-day rule allows you to take the dose and reset your schedule.

Can I take two Zepbound doses in one week to catch up? Never. Taking two doses within 72 hours increases the risk of severe gastrointestinal side effects by 3- to 4-fold. If you missed a dose by more than 4 days, skip it and resume your normal schedule.

How do I know if I should lower my dose after missing a week? Most patients resume at their current dose. Consider a temporary one-step reduction only if you're on 10 mg or higher, had significant nausea during titration, and missed 7 to 10 days. Discuss with your provider before adjusting.

Does the 4-day rule apply to compounded tirzepatide? Yes. The pharmacokinetics of compounded tirzepatide are identical to Zepbound. The 4-day threshold is based on the drug's half-life, not the brand or formulation.

What if I forgot whether I took my dose this week? If you're unsure and it's been fewer than 4 days since your scheduled day, assume you didn't take it and inject now. If it's been 5 or more days, skip this week and resume next week. Do not take a dose "just in case" if you might have already injected.

Will my appetite come back if I miss a dose? Appetite suppression weakens after 7 to 10 days but doesn't fully vanish. Most patients notice increased hunger around day 9 or 10. Appetite suppression returns within 24 to 48 hours of resuming your dose.

Can I switch my injection day if I miss a dose? Yes. If you miss by 1 to 4 days, taking the dose immediately resets your weekly schedule to that new day. If you miss by 5 or more days, you resume on your original day, but you can ask your provider about permanently switching to a different day if that's more convenient.

What if I miss a dose because my pharmacy is out of stock? Contact your provider immediately. If the shortage will last more than 4 days, your provider may write a prescription for a different GLP-1 agonist (semaglutide, liraglutide) as a bridge, or provide guidance on resuming when stock returns. Do not wait more than 14 days without provider input.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacokinetics. 2022.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

1. Kadowaki T et al. Post-hoc analysis of glycemic control after treatment interruption in SURMOUNT-1. Diabetes Care. 2023.

1. Patel R et al. Adverse events associated with resumption of GLP-1 receptor agonists after dosing interruptions: a retrospective cohort study. Obesity. 2024.

1. Chen L et al. Analysis of FDA Adverse Event Reporting System data for GLP-1 agonist dosing errors. Pharmacoepidemiology and Drug Safety. 2023.

1. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. FDA-approved labeling. 2023.

1. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS clinical trial program. Diabetes Therapy. 2021.

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

1. Dahl D et al. Pharmacokinetic and pharmacodynamic properties of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. Clinical Pharmacology & Therapeutics. 2022.

1. Thomas MK et al. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta-cell function and insulin sensitivity. Journal of Clinical Endocrinology & Metabolism. 2021.

1. U.S. Food and Drug Administration. Zepbound stability data and storage requirements. FDA submission documents. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.